(RTTNews) - Shuttle Pharmaceuticals Holdings, Inc. (SHPH), a specialty pharmaceutical company, on Tuesday announced it has reached 25% enrollment in the initial randomized portion of its Phase 2 clinical trial evaluating Ropidoxuridine or IPdR for the treatment of glioblastoma.
The trial is designed to determine the optimal dose of Ropidoxuridine in combination with radiation therapy for patients with the most aggressive form of brain cancer, IDH wild-type, methylation negative glioblastoma.
The trial aims to improve survival outcomes for patients who currently have limited treatment options, with radiation being the standard of care.
This Phase 2 study will initially randomize 40 patients into two groups (1,200 mg/day and 960 mg/day) to identify the optimal dose before enrolling additional patients. The study is conducted at leading cancer centers, including Georgetown University Medical Center, UNC Medical Center, and John Theurer Cancer Center.
Shuttle Pharma previously received Orphan Drug Designation from the FDA for Ropidoxuridine in glioblastoma treatment, providing potential marketing exclusivity upon approval.
The company is on track to complete enrollment in the coming months, with results expected to drive future clinical development for glioblastoma.
Currently, SHPH is trading at $0.86 down by 2.69%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
